Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Drospirenone,Estetrol

            Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Nextstellis

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Mithra Pharmaceuticals

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 27, 2021

            Details:

            NEXTSTELLIS (drospirenone and estetrol tablets) indicated for use by females of reproductive potential to prevent pregnancy. Nextstellis® has been granted marketing exclusivity as a new chemical entity from the US Food and Drug Administration (FDA).